The mean LVEF in the early and delayed cohorts was 27.1 and 20.6%, respectively; however, many patients were not on optimal medical therapy for heart failure: Only 50 to 60% had an ACEI/ARB, and the use of mineralocorticoid receptor antagonists and sacubitril/valsartan was not reported. The gene discussed is NR3C2; the disease is heart failure.